These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34330748)

  • 1. Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    J Pharmacol Exp Ther; 2021 Oct; 379(1):74-84. PubMed ID: 34330748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease.
    Schiefer J; Sprünken A; Puls C; Lüesse HG; Milkereit A; Milkereit E; Johann V; Kosinski CM
    Brain Res; 2004 Sep; 1019(1-2):246-54. PubMed ID: 15306259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescue of BDNF expression by the thalamic parafascicular nucleus with chronic treatment with the mGluR2/3 agonist LY379268 may contribute to the LY379268 rescue of enkephalinergic striatal projection neurons in R6/2 Huntington's disease mice.
    Wang H; Del Mar N; Deng Y; Reiner A
    Neurosci Lett; 2021 Oct; 763():136180. PubMed ID: 34416343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice.
    Li SH; Colson TL; Abd-Elrahman KS; Ferguson SSG
    Front Mol Neurosci; 2022; 15():801757. PubMed ID: 35185467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
    Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
    Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.
    Reiner A; Wang HB; Del Mar N; Sakata K; Yoo W; Deng YP
    Brain Res; 2012 Sep; 1473():161-72. PubMed ID: 22820300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mGluR5 antagonism increases autophagy and prevents disease progression in the
    Abd-Elrahman KS; Hamilton A; Hutchinson SR; Liu F; Russell RC; Ferguson SSG
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice.
    Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2019 Apr; 12(1):35. PubMed ID: 30961637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease.
    Peng Q; Wu B; Jiang M; Jin J; Hou Z; Zheng J; Zhang J; Duan W
    PLoS One; 2016; 11(2):e0148839. PubMed ID: 26859386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early defect of transforming growth factor β1 formation in Huntington's disease.
    Battaglia G; Cannella M; Riozzi B; Orobello S; Maat-Schieman ML; Aronica E; Busceti CL; Ciarmiello A; Alberti S; Amico E; Sassone J; Sipione S; Bruno V; Frati L; Nicoletti F; Squitieri F
    J Cell Mol Med; 2011 Mar; 15(3):555-71. PubMed ID: 20082658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.
    Engel M; Snikeris P; Matosin N; Newell KA; Huang XF; Frank E
    Psychopharmacology (Berl); 2016 Apr; 233(8):1349-59. PubMed ID: 26861891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons.
    Wang MJ; Li YC; Snyder MA; Wang H; Li F; Gao WJ
    PLoS One; 2013; 8(4):e61787. PubMed ID: 23593498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity.
    Woolley ML; Pemberton DJ; Bate S; Corti C; Jones DN
    Psychopharmacology (Berl); 2008 Feb; 196(3):431-40. PubMed ID: 18057917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum.
    Di Liberto V; Mudò G; Belluardo N
    Neuropharmacology; 2011 Sep; 61(4):638-45. PubMed ID: 21619889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Huntington's disease phenotype progression in male and female heterozygous FDNQ175 mice.
    Li SH; Colson TL; Chen J; Abd-Elrahman KS; Ferguson SSG
    Mol Brain; 2023 Sep; 16(1):67. PubMed ID: 37726802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment with mGluR2 or mGluR3 Agonists Reduces Apoptosis Induced by Hypoxia-Ischemia in Neonatal Rat Brains.
    Bratek-Gerej E; Bronisz A; Ziembowicz A; Salinska E
    Oxid Med Cell Longev; 2021; 2021():8848015. PubMed ID: 33763176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental enrichment and a selective metabotropic glutamate receptor
    Garcia EJ; Cain ME
    Pharmacol Biochem Behav; 2020 May; 192():172907. PubMed ID: 32179027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington's disease.
    Yu D; Zarate N; White A; Coates D; Tsai W; Nanclares C; Cuccu F; Yue JS; Brown TG; Mansky RH; Jiang K; Kim H; Nichols-Meade T; Larson SN; Gundry K; Zhang Y; Tomas-Zapico C; Lucas JJ; Benneyworth M; Öz G; Cvetanovic M; Araque A; Gomez-Pastor R
    Acta Neuropathol Commun; 2022 Jun; 10(1):83. PubMed ID: 35659303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.